Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Salarius Ltd Appoints CEO

1 Aug 2018 07:00

RNS Number : 3847W
Tekcapital plc
01 August 2018
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

1 August 2018

Tekcapital plc

("Tekcapital" or the "Company")

 

Salarius Ltd Appoints CEO

 

 

Tekcapital plc (AIM: TEK), the UK intellectual property (IP) investment group focused on creating marketplace value from university technology, announces that its portfolio company Salarius Ltd ("Salarius"), the developer and producer of Microsalt; a proprietary and patented low-sodium salt product, has appointed Victor H. Manzanilla as its CEO. 

 

Mr. Manzanilla has significant business management experience in Fortune 500 companies. His expertise is focused on building and leading teams, developing and strengthening both new and global brands and delivering financial performance.

 

Mr. Manzanilla previously served as Marketing Director for Office Depot®, a leading provider of business services and supplies, products and technology solutions through its fully integrated omni-channel platform of approximately 1,400 stores. Additionally, Victor enjoyed a 12-year career at Procter & GambleTM, holding several positions including Home Care Marketing Innovation Manager and Brand Manager for Global New Business Development for Febreze®.

 

More recently, Victor served as CEO of VHM Global Research. He has authored two books published by HarperCollins, Awaken Your Inner Hero and Your Moment is Now, and writes a blog which has more than 1M followers.

 

Concomitant with his appointment, Mr Manzanilla has purchased 2.5% of the shares of Salarius through his consulting firm VHM Global Research for $50,000. Following this purchase, Tekcapital owns 97.5% of the share capital of Salarius.

 

Dr. Clifford Gross, Chairman at Tekcapital commented: "We are delighted that Salarius has appointed Victor Manzanilla as its CEO. We believe he is a remarkable individual with the skills and experience necessary to build a global brand utilizing Salarius' proprietary low-sodium technology. Now more than ever, consumers require healthy options to improve their wellbeing and Salarius' goal is to enable them to have these choices with significantly less sodium. We consider the appointment of Victor Manzanilla as a significant milestone in the development and commercialization of Salarius."

 

About Salarius, Ltd.

 

Salarius has developed a patented process for producing the world's smallest edible salt crystals. Use of these crystals for topical food applications can deliver all of the flavour customers expect with about half of the sodium versus traditional salt. The mission of Salarius is to commercialize low-sodium Microsalt to improve the nutritional content of food and the health of individuals worldwide. To learn more, please visit www.salarius.co.

 

 

 

 

 

 

For further information, please contact:

Tekcapital plc

Clifford M Gross, Ph.D.

 

Via Walbrook PR

 

finnCap Ltd (Nominated Adviser and Joint Broker)

+ 44 (0) 20 7220 0500

Geoff Nash / Max Bullen-Smith (Corporate Finance)

Alice Lane/Camille Gochez (ECM)

 

Dowgate Capital Stockbrokers (Joint Broker)

+44 (0) 1293 517744

David Poutney / James Serjeant

 

Walbrook PR Ltd

+44 (0) 20 7933 8780

Paul Cornelius / Sam Allen / Nick Rome

tekcapital@walbrookpr.com

 

Tekcapital plc - The World's Largest University Network for Open Innovation

 

Tekcapital's objective is to create value from investing in new, university-developed intellectual properties. Additionally, using its proprietary discovery search engine, linked to 4,500+ universities in 160 countries, coupled with expert scientific review, Tekcapital provides a range of IP investment services to make it easy for organisations to find, evaluate, acquire and license university-developed technology. Tekcapital plc is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in Oxford, in the UK. For more information, please visit www.tekcapital.com

 

LEI: 213800GOJTOV19FIFZ85

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAEAKXFDDSPEFF
Date   Source Headline
27th May 20267:00 amRNSResults for Year Ended 31 December 2025
22nd May 20267:00 amRNSTekcapital takes stake in geothermal AI firm
21st May 20267:00 amRNSNew Orders
28th Apr 20267:00 amRNSStrategic Resale Alliance with Cardinal IP
18th Feb 20267:00 amRNSNotification of Major Holdings
10th Feb 20267:00 amRNSConditional Placing of £1.5 million
15th Jan 20267:00 amRNSCorporate Update
7th Jan 20267:00 amRNS-RPorfolio Company Update - Innovative Eyewear Inc
12th Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
1st Dec 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
19th Nov 20257:00 amRNSPortfolio Company Update - Guident Corp
13th Nov 20257:00 amRNSInnovative Eyewear Q3 Unaudited Financial Results
13th Nov 20257:00 amRNSTrading Statement
10th Nov 20257:00 amRNS-RStrategic Alliance signed with Nexscient Inc
4th Nov 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
17th Oct 20254:15 pmRNSNotification of Major Holdings
13th Oct 20251:44 pmRNSPlacing of £0.37 Million
10th Oct 20257:00 amRNSNew Product Launch – Invention Validator
8th Oct 202510:53 amRNSReplacement - Unaudited Half-Yearly Report
7th Oct 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear
6th Oct 20257:00 amRNSReplacement RNS: Half-year Report
30th Sep 20257:02 amRNSCommercial Strategy Update & New Products
30th Sep 20257:00 amRNSHalf-year Report
25th Sep 20257:00 amRNS-RPortfolio Company Update -Guident
24th Sep 20257:00 amRNSUnaudited Half Yearly Report
18th Sep 20257:00 amRNSPortfolio Company Update -Guident Proposed US IPO
10th Sep 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear
29th Aug 20257:00 amRNS-RPortfolio Company Update Guident Corp
19th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
15th Aug 20257:00 amRNS-RPortfolio Company Update Innovative Eyewear Q2
13th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
6th Aug 20257:00 amRNS-RPortfolio Company Update - Guident Corp
25th Jul 20257:00 amRNSTrading Statement
24th Jul 20257:00 amRNS-RPortfolio Company Update - Guident Corp
21st Jul 20257:00 amRNS-RPortfolio Company Update- Innovative Eyewear
27th Jun 202512:39 pmRNSResult of AGM
19th Jun 20251:06 pmRNSNotification of Major Holdings
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
19th Jun 20257:00 amRNS-RPortfolio Company Update - Guident Corp
10th Jun 20257:00 amRNSContract Win
2nd Jun 20257:02 amRNSNotice of AGM
2nd Jun 20257:00 amRNSFinal Results Year Ended 31 December Notice of AGM
2nd Jun 20257:00 amRNSFundraising of £1.25 Million
29th May 20257:00 amRNS-RPortfolio Company Update - Innovative Eyewear Inc
23rd May 20257:00 amRNSFinal Results Year Ended 31 December 2024
16th May 20257:00 amRNS-RPortfolio Company Update - Guident Corp
12th May 20257:00 amRNSPortfolio Company Update:Guident Corp Proposed IPO
6th May 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc.
28th Apr 20257:00 amRNSPortfolio Company Update - Innovative Eyewear Inc
24th Apr 20257:00 amRNSQ1 2025 Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.